Navigation Links
AMDL Signs Letter of Intent to Purchase China-Based Pharmaceutical Distribution Company
Date:7/1/2008

TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a leading vertically integrated bio-pharmaceutical company headquartered in Tustin, California, with major operations in the U.S. and China, announced today a letter of intent (LOI) has been signed between AMDL's wholly-owned subsidiary Jade Pharmaceutical Inc. (JPI) and China-based Sichuan ZhiTong Pharmaceutical, Ltd. (SZP). SZP is a privately-held China-based pharmaceutical distribution company that sells and distributes traditional Chinese medicines, health foods, medical equipment, and generic pharmaceutical products.

SZP has been a distributor for AMDL since the fourth quarter of 2007, selling the company's Domperidone anti-emetic product. SZP sells approximately $100,000 per month of Domperidone and AMDL expects these sales levels to increase to at least $200,000 per month over the next 60 days for this product due to increased marketing efforts. Under the terms of the LOI, SZP and JPI will consolidate sales forces and enter into a distribution agreement where SZP will distribute additional AMDL pharmaceutical products including GoodNak, Levofloxicin and Ondansetron. SZP currently employs approximately 80 in-house sales agents.

AMDL, JPI and SZP have agreed to retain an independent China-based business valuation company to determine the value of SZP. Based upon that valuation and negotiations between JPI and SZP, an acquisition price will be determined and acquisition consideration will be allocated that may include cash, common stock of AMDL, and/or stock options to purchase common shares of AMDL. Prior to signing the definitive agreement, SZP and JPI have agreed to engage an international accounting firm to complete a two-year audit of SZP in accordance with GAAP accounting standards. Prior to executing a Definitive Agreement, both JPI and SZP will work together to create a new two-year business plan and capital budget.

In FY2007, SZP had gross sales of approximately $24 million and anticipates FY2008 sales of $35.7 million with approximately 10% net after-tax profit margins. Subject to due diligence by JPI and other conditions, JPI may acquire up to 100 percent ownership in SZP. Best efforts will be made by both JPI and SZP to complete the purchase of SZP by October 1, 2008.

AMDL has terminated a previously announced LOI to acquire Guangzhou Lazon Pharmacy Co., Ltd. (GLP), a Guangzhou-based distributor based on material uncovered through the due diligence process.

About AMDL:

AMDL, Inc. is a specialty pharmaceutical company. The Company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary Jade, currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact:

AMDL Communications

Kristine Szarkowitz

206/310-5323

Kszarkowitz@amdl.com


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Second International Conference on Signs of Autism in Infants: Changing Outcomes through Early Identification and Intervention, October 11 and 12, 2008. Save the Date!
2. Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement
3. Go Healthy Signs Marketing Contract with AIM Marketing
4. FHS Corp Signs Partnership Agreement With Concuity
5. Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc.
6. ACTS Retirement-Life Communities Signs Land Purchase Agreement on 48-Acre Site in Matthews, North Carolina
7. HighPoint Solutions Signs Deal to Implement Model N Managed Care and Government Pricing System for Specialty Pharmaceutical Company
8. XRKade Signs 50th Location in North America and Announces Expansion Plans
9. Governor Rendell Signs Bill Restricting Smoking in Most Public Places in Pennsylvania
10. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
11. 1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... According to the American ... each year, putting it among the top 5 most popular minimally-invasive cosmetic procedures in ... million-plus procedures will be performed over the next 8-10 weeks. For anyone considering a ...
(Date:3/30/2017)... NC (PRWEB) , ... March 30, 2017 , ... ... will host the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ... 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent readmissions ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... St. Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... Often called the "Spice of Life" or "Wonder Spice", it has been used for ... extensive use in the East," says Heshelow, author of " Turmeric: How to Use ...
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... March 30, 2017  Lannett Company, Inc. (NYSE: ... made a $25 million payment against its existing revolving ... combined with the $75 million payment we made earlier ... million in annualized cash interest expense, at current rates" ... Lannett.  "Our business is solid and we continue to ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Neuromonitoring (IONM) Market Size & Forecast By Type (Insource IONM, ... 2025" report to their offering. ... The global Intraoperative Neuromonitoring ... 2025. The intraoperative neuromonitoring market is anticipated to witness significant ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
Breaking Medicine Technology: